Treatment of severe refractory adult atopic dermatitis with ustekinumab

International Journal of Dermatology

Volumn 51, Issue 1, 2012, Pages 115-116

  Puya, Rafael ^a   Alvarez López, Maria ^a   Velez, Antonio ^a   Asuncion, Enrique Casas ^a   Moreno, José Carlos ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; EFALIZUMAB; PREDNISONE; USTEKINUMAB;

ADULT; ATOPIC DERMATITIS; CASE REPORT; CAUCASIAN; HUMAN; IMMUNE RESPONSE; LETTER; MALE; PHOTOTHERAPY; SINGLE DRUG DOSE; SKIN ALLERGY;

ANTIBODIES, MONOCLONAL; CYCLOSPORINE; DERMATITIS, ATOPIC; ECZEMA; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PREDNISONE; PRURITUS; SEVERITY OF ILLNESS INDEX; ULTRAVIOLET THERAPY; YOUNG ADULT;

EID: 84055189183     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2011.05195.x     Document Type: Letter

References (5)

1. Leung DY, Boguniewicz M, Howell MD, Nomura I, Hamid QA. New insights into atopic dermatitis. J Clin Invest 2004; 113: 651-657.
2. Kikly K, Liu L, Na S, Sedgwick JD. The IL-23/Th17 axis: therapeutic targets for autoimmune inflammation. Curr Opin Immunol 2006; 18: 670-675.
3. Louten J, Boniface K, de Waal Malefyt R. Development and function of Th17 cells in health and disease. J Allergy Clin Immunol 2009; 123: 1004-1011.
4. Toda M, Leung DYM, Molet S, et al. Polarized in vivo expression of IL-11 and IL-17 between acute and chronic skin lesions. J Allergy Clin Immunol 2003; 111: 875-888.
5. Koga C, Kabashima K, Shiraishi N, Kobayashi M, Tokura Y. Possible pathogenic role of Th17 cells for atopic dermatitis. J Invest Dermatol 2008; 128: 2615-2630.